|
|
Vaccine Detail
|
MV-014-212 |
| Vaccine Information |
- Vaccine Name: MV-014-212
- Target Pathogen: SARS-CoV-2
- Target Disease: COVID-19
- Manufacturer: Meissa Vaccines, Inc.
- Vaccine Ontology ID: VO_0005240
- Type: Live, attenuated vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: Spike Protein of SARS-CoV-2
- Immunization Route: intranasal immunization
- Description: MV-014-212, is a live attenuated vaccine against respiratory syncytial virus (RSV) that is expressing the spike (S) protein of SARS-CoV-2. MV-014-212 is administered as drops or a spray in the nose.
|
| Host Response |
|
|
| References |
|
|
|
